Evidence map›Paper›PMID 29101636›Full record

ArticleMolecular imaging and biology2018

LyP-1 Conjugated Nanoparticles for Magnetic Resonance Imaging of Triple Negative Breast Cancer.

Abedelnasser Abulrob, Slavisa Corluka, Barbara Blasiak, B Gino Fallone, Dragana Ponjevic, John Matyas, Boguslaw Tomanek

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Contrast media & molecular imaging · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Abedelnasser AbulrobDepartment of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. Abedelnasser.abulrob@nrc.gc.ca.ORCID 0000-0002-7617-9735
Slavisa CorlukaDepartment of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Barbara BlasiakInstitute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland.
B Gino FalloneDepartment of Oncology, University of Alberta, Edmonton, Canada.
Dragana PonjevicDepartment of Comparative Biology & Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
John MatyasDepartment of Comparative Biology & Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
Boguslaw TomanekInstitute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland. tomanek@ualberta.ca.
University of Calgary · CAUniversity of Alberta · CANatural Sciences and Engineering Research Council of Canada · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTriple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, or Her2/neu. Both diagnosis and treatment of TNBC remain a clinical challenge. LyP-1 is a cyclic 9 amino acid peptide that can bind to breast cancer cells. The goal of this study was to design and characterize LyP-1 conjugated to fluorescent iron oxide nanoparticles (LyP-1-Fe PROCEDURES: The binding of LyP-1-Fe

resultsImmunofluorescence revealed dense binding of the LyP-1-Fe

conclusionThe results demonstrate that LyP-1-Fe

Indexed as

Magnetic Resonance ImagingAnimalsCell Line, TumorFemaleFluorescenceHumansMice, NudeNanoparticlesPeptides, CyclicTriple Negative Breast NeoplasmsLyP-1 peptidePeptides, CyclicBreast cancerIron oxide nanoparticlesLYP1 peptideMolecular imagingMRIOptical imagingTriple negative

Identifiers

PMID29101636
OpenAlexW2766197375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.